Back to Awarded Treatment Trials


Awarded Trial: 03T-471

Grant ID

03T-471

Illness

Schizophrenia

Primary Drug/Intervention

Epigallocatechin Gallate (EGCG)

Primary Dosage

up to 1600mg/day

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Berger

Sample Size

40

Duration of Study Period for Each Subject

10 weeks

Outcome Measurements

CGI, PANSS, SANS, HAM-D, HAM-A, AIMS

Results

Epigallocatechin gallate (EGCG) is an ingredient of green tea and thought to have effects on nitric acid and glutamate receptors. It is available in health food stores. The researchers randomized 34 patients with schizophrenia to EGCG 1600 mg/d or placebo for 8 wks. There were 9 dropouts and 25 completers. Both groups improved, and there was no statistical difference between them. It was thus a negative trial.

Publication

N/A

Link

N/A

PI Name

S. Paul Berger

Degree

MD

Center

N/A

Institution

Portland Veterans Affairs Medical Center

Address

3710 SW US Veterans Hospital Road R&D 64

City or Town

Portland

State or Province

OR

Zip or Postal Code

97239

Country

USA

Email Address

bergerp@ohsu.edu